Skip to Content

'
Francisco J. Esteva, MD, PhD

Present Title & Affiliation

Primary Appointment

Professor, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Professor, Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX

Bio Statement

Dr. Francisco J. Esteva moved to the United States after receiving his medical degree from the University of Zaragoza Faculty of Medicine in his native Spain. He completed a residency in internal medicine at Cooper Hospital/University Medical Center (Camden, NJ) and a fellowship in medical oncology at Georgetown University Medical Center (Washington, DC). In 1997 Dr. Esteva was recruited by The University of Texas MD Anderson Cancer Center, where he contributed to the development of an internationally recognized program in clinical and translational research in breast cancer. In 2001 Dr. Esteva received a Ph.D. degree from his alma mater. In 2010 he was inducted as a member of the American Society for Clinical Investigation. Dr. Esteva is dedicated to the development of novel therapies for breast cancer, with a passion for improving the survival and quality of life of cancer patients through innovative research and compassionate patient care.

Research Interests

Dr. Esteva directed the Breast Cancer Translational Research Laboratory at MD Anderson Cancer Center for 6 years and currently serves as the Director of the Breast Cancer Serum Bank. Research interests include biomarkers, targeted therapies, mechanisms of drug resistance, translational research and investigator-initiated clinical trials. Dr. Esteva has become a leader in the clinical application of biomarkers, such as HER2 in cancer patients. His laboratory was the first to report synergism between the HER2-directed monoclonal antibodies trastuzumab and pertuzumab in breast cancer. This finding was subsequently confirmed in clinical trials, resulting in the 2012 FDA approval of this combination for patients with HER2 positive metastatic breast cancer. More recent work has focused on the role of HER2 mutations in resistance to HER2-targeted therapy. Another area of research is the impact of obesity and obesity treatments in breast cancer. All of his work has significant implications for novel clinical trials in patients with breast cancer, some of which are completed or in progress. Dr. Esteva is considered to be an expert in the field of clinical research of breast cancer, especially in regards to targeted therapies. He lectures and publishes extensively regarding the management of patients with breast cancer. Reflecting his expertise, Dr. Esteva serves as co-chair of the HER2 working group at SWOG, he is a member of the Systemic Therapy for Women with Advanced HER2 Positive Breast Cancer Expert Panel for the American Society of Clinical Oncology, and he is on the editorial boards of several leading cancer journals.

Clinical Interests

Diagnosis, prevention and treatment of breast cancer. 

Education & Training

Degree-Granting Education

2001 University of Zaragoza, Zaragoza, Spain, PhD, Cum Laude, Medical Sciences
1988 University of Zaragoza Faculty of Medicine, Zaragoza, Spain, MD, Medicine and Surgery

Postgraduate Training

7/1994-6/1996 Clinical Fellowship, Medical Oncology, Georgetown University Medical Center, Washington, DC, Program Director, Kevin Cullen, M.D.
7/1992-6/1994 Clinical Residency, Internal Medicine, Cooper Hospital/University Medical Center, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, Camden, NJ, Chairman, Edward Viner, M.D.
7/1991-6/1992 Clinical Internship, Internal Medicine, Cooper Hospital/University Medical Center, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, Camden, NJ, Chairman, Edward Viner, M.D.

Board Certifications

1997 American Board of Internal Medicine, Medical Oncology
1994 American Board of Internal Medicine, Internal Medicine

Honors and Awards

2010 Elected Member, American Society for Clinical Investigation
2009-2013 Best Doctors in America
2003 Outstanding Educator, The University of Texas MD Anderson Cancer Center
2001 Elected Fellow of the American College of Physicians
2000 The Paul N. Larson Lecture in Breast Disease, University of Minnesota Medical School
1999 NCI Mentored Patient-Oriented Research Career Development Award
1983 Honorary Intern Student, Dept. of Biochemistry, University of Zaragoza Faculty of Medicine

Professional Memberships

American Association for Cancer Research
Member, 1992-present
American College of Physicians
Fellow, 2002-present
American Society of Breast Disease
Member, 2002-present
American Society of Clinical Oncology
Mentor, International Development and Education Award, 2005-2009
Member, Cancer Education Committee, 2004-2007
Member, Program Committee, 2001
Member, 1996-present
European Society for Medical Oncology
Member, 2003-present
SWOG
Liaison, Early Therapeutics Committee, 2010-present
Member, Breast Cancer Working Group, 2008-present
The American Society for Clinical Investigation
Member, 2010-present

Selected Publications

Peer-Reviewed Original Research Articles
1. Andre F, Conforti R, Moeder CB, Mauguen A, Arnedos M, Berrada N, Delaloge S, Tomasic G, Spielmann M, Esteva FJ, Rimm DL, Michiels S. Association between the nuclear to cytoplasmic ratio of p27 and the efficacy of adjuvant polychemotherapy in early breast cancer. Ann Oncol 23(8):2059-64, 2012. PMID: 22241898.
2. Iwamoto T, Booser D, Valero V, Murray JL, Koenig K, Esteva FJ, Ueno NT, Zhang J, Shi W, Qi Y, Matsuoka J, Yang EJ, Hortobagyi GN, Hatzis C, Symmans WF, Pusztai L. Estrogen Receptor (ER) mRNA and ER-Related Gene Expression in Breast Cancers That Are 1% to 10% ER-Positive by Immunohistochemistry. J Clin Oncol 30(7):729-34, 2012. PMID: 22291085.
3. Bartholomeusz C, Oishi T, Saso H, Akar U, Liu P, Kondo K, Kazansky A, Krishnamurthy S, Lee J, Esteva FJ, Kigawa J, Ueno NT. MEK1/2 Inhibitor Selumetinib (AZD6244) Inhibits Growth of Ovarian Clear Cell Carcinoma in a PEA-15-Dependent Manner in a Mouse Xenograft Model. Mol Cancer Ther 11(2):360-9, 2012. PMCID: PMC3320047.
4. He X, Esteva FJ, Ensor J, Hortobagyi GN, Lee MH, Yeung SC. Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2+ breast cancer. Ann Oncol 23(7):1771-80, 2012. PMCID: PMC3387820.
5. Jung EJ, Santarpia L, Kim J, Esteva FJ, Moretti E, Buzdar AU, Di Leo A, Le XF, Bast RC, Park ST, Pusztai L, Calin GA. Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients. Cancer 118(10):2603-14, 2012. PMID: 22370716.
6. Liu JC, Voisin V, Bader GD, Deng T, Pusztai L, Symmans WF, Esteva FJ, Egan SE, Zacksenhaus E. Seventeen-gene signature from enriched Her2/Neu mammary tumor-initiating cells predicts clinical outcome for human HER2+:ERα- breast cancer. Proc Natl Acad Sci U S A 109(15):5832-7, 2012. PMCID: PMC3326451.
7. Arun B, Valero V, Liu D, Brewster A, Green M, Gutierrez-Barrera A, Akar U, Rivera E, Esteva FJ, Buzdar AU, Hortobagyi GN, Sneige N. Short-term biomarker modulation prevention study of Anastrozole in women at increased risk for second primary breast cancer. Cancer Prev Res (Phila) 5(2):276-82, 2012. PMID: 22102688.
8. Carey LA, Rugo HS, Marcom PK, Mayer EL, Esteva FJ, Ma CX, Liu MC, Storniolo AM, Rimawi MF, Forero-Torres A, Wolff AC, Hobday TJ, Ivanova A, Chiu WK, Ferraro M, Burrows E, Bernard PS, Hoadley KA, Perou CM, Winer EP. TBCRC 001: Randomized Phase II Study of Cetuximab in Combination With Carboplatin in Stage IV Triple-Negative Breast Cancer. J Clin Oncol 30(21):2615-23, 2012. PMCID: PMC3413275.
9. Kuerer HM, Buzdar AU, Mittendorf EA, Esteva FJ, Lucci A, Vence LM, Radvanyi L, Meric-Bernstam F, Hunt KK, Symmans WF. Biologic and immunologic effects of preoperative trastuzumab for ductal carcinoma in situ of the breast. Cancer 117(1):39-47, 2011. PMCID: PMC2997136.
10. Baek JM, Jin Q, Ensor J, Boulbes DR, Esteva FJ. Serum CD44 levels and overall survival in patients with HER2-positive breast cancer. Breast Cancer Res Treat 130(3):1029-36, 2011. PMID: 21830016.
11. Juul N, Szallasi Z, Eklund AC, Li Q, Burrell RA, Gerlinger M, Valero V, Andreopoulou E, Esteva FJ, Symmans WF, Desmedt C, Haibe-Kains B, Sotiriou C, Pusztai L, Swanton C. Assessment of an RNA interference screen-derived mitotic and ceramide pathway metagene as a predictor of response to neoadjuvant paclitaxel for primary triple-negative breast cancer: a retrospective analysis of five clinical trials. Lancet Oncol 11(4):358-65, 2010. PMID: 20189874.
12. Shen Y, Tolic N, Liu T, Zhao R, Petritis BO, Gritsenko MA, Camp DG, Moore RJ, Purvine SO, Esteva FJ, Smith RD. Blood Peptidome-Degradome Profile of Breast Cancer. PLoS One 5(10):e13133, 2010. PMCID: PMC2956627.
13. Kulkarni S, Reddy KB, Esteva FJ, Moore HC, Budd GT, Tubbs RR. Calpain regulates sensitivity to trastuzumab and survival in HER2-positive breast cancer. Oncogene 29(9):1339-50, 2010. PMID: 19946330.
14. Jin Q, Yuan LX, Boulbes DR, Baek JM, Wang YN, Gomez-Cabello D, Hawke DH, Yeung SC, Lee MH, Hortobagyi GN, Hung MC, Esteva FJ. Fatty acid synthase phosphorylation: a novel therapeutic target in HER2-overexpressing breast cancer cells. Breast Cancer Res 12(6):R96, 2010. PMID: 21080941.
15. Huang X, Gao L, Wang S, McManaman JL, Thor AD, Yang X, Esteva FJ, Liu B. Heterotrimerization of the growth factor receptors erbB2, erbB3, and insulin-like growth factor-I receptor in breast cancer cells resistant to Herceptin. Cancer Res 70(3):1204-14, 2010. PMID: 20103628.
16. Bartholomeusz C, Gonzalez-Angulo AM, Kazansky A, Krishnamurthy S, Liu P, Yuan LX, Yamasaki F, Liu S, Hayashi N, Zhang D, Esteva FJ, Hortobagyi GN, Ueno NT. PEA-15 inhibits tumorigenesis in an MDA-MB-468 triple-negative breast cancer xenograft model through increased cytoplasmic localization of activated extracellular signal-regulated kinase. Clin Cancer Res 16(6):1802-11, 2010. PMID: 20215547.
17. Esteva FJ, Guo H, Zhang S, Santa-Maria C, Stone S, Lanchbury JS, Sahin AA, Hortobagyi GN, Yu D. PTEN, PIK3CA, p-AKT, and p-p70S6K Status. Association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer. Am J Pathol 177(4):1647-56, 2010. PMCID: PMC2947262.
18. Liang K, Esteva FJ, Albarracin C, Stemke-Hale K, Lu Y, Bianchini G, Yang CY, Li Y, Li X, Chen CT, Mills GB, Hortobagyi GN, Mendelsohn J, Hung MC, Fan Z. Recombinant human erythropoietin antagonizes trastuzumab treatment of breast cancer cells via Jak2-mediated Src activation and PTEN inactivation. Cancer Cell 18(5):423-35, 2010. PMCID: PMC3022383.
19. Zhang D, LaFortune TA, Krishnamurthy S, Esteva FJ, Cristofanilli M, Liu P, Lucci A, Singh B, Hung MC, Hortobagyi GN, Ueno NT. Epidermal growth factor receptor tyrosine kinase inhibitor reverses mesenchymal to epithelial phenotype and inhibits metastasis in inflammatory breast cancer. Clin Cancer Res 15(21):6639-48, 2009. PMCID: PMC2783487.
20. Gilcrease MZ, Woodward WA, Nicolas MM, Corley LJ, Fuller GN, Esteva FJ, Tucker SL, Buchholz TA. Even low-level HER2 expression may be associated with worse outcome in node-positive breast cancer. Am J Surg Pathol 33(5):759-67, 2009. PMID: 19252432.
21. Mittendorf EA, Wu Y, Scaltriti M, Meric-Bernstam F, Hunt KK, Dawood S, Esteva FJ, Buzdar AU, Chen H, Eksambi S, Hortobagyi GN, Baselga J, Gonzalez-Angulo AM. Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes. Clin Cancer Res 15(23):7381-8, 2009.
22. Dawood S, Broglio, Esteva FJ, Yang W, Kau SW, Islam R, Albarracin C, Yu TK, Green M, Hortobagyi GN, Gonzalez-Angulo AM. Survival among women with triple receptor-negative breast cancer and brain metastases. Ann Oncol 20(4):621-7, 2009. PMID: 19150943.
23. Moulder SL, Symmans WF, Booser DJ, Madden TL, Lipsanen C, Yuan L, Brewster AM, Cristofanilli M, Hunt KK, Buchholz TA, Zwiebel J, Valero V, Hortobagyi GN, Esteva FJ. Phase I/II study of G3139 (Bcl-2 antisense oligonucleotide) in combination with doxorubicin and docetaxel in breast cancer. Clin Cancer Res 14(23):7909-16, 12/2008. PMID: 19047121.
24. Weisenberger DJ, Trinh BN, Campan M, Sharma S, Long TI, Ananthnarayan S, Liang G, Esteva FJ, Hortobagyi GN, McCormick F, Jones PA, Laird PW. DNA methylation analysis by digital bisulfite genomic sequencing and digital MethyLight. Nucleic Acids Res 36(14):4689-98, 2008. PMCID: PMCPMC2504308.
25. Andre F, Nahta R, Conforti R, Boulet T, Aziz M, Yuan LX, Meslin F, Spielmann M, Tomasic G, Pusztai L, Hortobagyi GN, Michiels S, Delaloge S, Esteva FJ. Expression patterns and predictive value of phosphorylated AKT in early-stage breast cancer. Ann Oncol 19(2):315-20, 2008. PMID: 17804473.
26. Peintinger F, Buzdar AU, Kuerer HM, Mejia JA, Hatzis C, Gonzalez-Angulo AM, Pusztai L, Esteva FJ, Dawood SS, Green MC, Hortobagyi GN, Symmans WF. Hormone receptor status and pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab. Ann Oncol 19(12):2020-5, 2008. PMID: 18667396.
27. Sturgeon CM, Duffy MJ, Stenman UH, Lilja H, Brünner N, Chan DW, Babaian R, Bast RC, Dowell B, Esteva FJ, Haglund C, Harbeck N, Hayes DF, Holten-Andersen M, Klee GG, Lamerz R, Looijenga LH, Molina R, Nielsen HJ, Rittenhouse H, Semjonow A, Shih IeM, Sibley P, Sölétormos G, Stephan C, Sokoll L, Hoffman BR, Diamandis EP, Diamandis EP. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem 54(12):e11-79, 2008. PMID: 19042984.
28. Brewster AM, Hortobagyi GN, Broglio KR, Kau SW, Santa-Maria CA, Arun B, Buzdar AU, Booser DJ, Valero V, Bondy M, Esteva FJ. Residual risk of breast cancer recurrence 5 years after adjuvant therapy. J Natl Cancer Inst 100(16):1179-83, 2008. PMID: 18695137.
29. Shen Y, Dong W, Esteva FJ, Kau SW, Theriault RL, Bevers TB. Are there racial differences in breast cancer treatments and clinical outcomes for women treated at M.D. Anderson Cancer Center. Breast Cancer Res Treat 102(3):347-56, 5/2007. PMID: 17028980.
30. Esteva FJ, Wang J, Lin F, Mejia JA, Yan K, Altundag K, Valero V, Buzdar AU, Hortobagyi GN, Symmans WF, Pusztai L. CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer. (Abstracted in The BCN (BreastCancer.Net) News, January 15, 2008). Breast Cancer Res 9(8):R87, 2007. PMID: 18086299.
31. Nahta R, Yuan LX, Du Y, Esteva FJ. Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: Effects on insulin-like growth factor I signaling. Mol Cancer Ther 6:667-74, 2007. PMID: 17308062.
32. Buzdar AU, Valero V, Ibrahim NK, Francis D, Broglio KR, Theriault RL, Pusztai L, Green MC, Singletary SE, Hunt KK, Sahin AA, Esteva FJ, Symmans WF, Ewer MS, Buchholz TA, Hortobagyi GN. Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res 13(1):228-33, 2007. PMID: 17200359.
33. Nahta R, Yuan LX, Fiterman DJ, Zhang L, Symmans WF, Ueno NT, Esteva FJ. B cell translocation gene 1 contributes to antisense Bcl-2-mediated apoptosis in breast cancer cells. Mol Cancer Ther 5:1593-601, 2006. PMID: 16818519.
34. Gonzalez-Angulo AM, Guarneri V, Gong Y, Cristofanilli M, Morales-Vasquez F, Sneige N, Hortobagyi GN, Esteva FJ. Downregulation of the cyclin-dependent kinase inhibitor p27kip1 might correlate with poor disease-free and overall survival in inflammatory breast cancer. Clin Breast Cancer 7:326-30, 2006. PMID: 17092400.
35. Guarneri V, Lenihan DJ, Valero V, Durand JB, Broglio K, Hess KR, Michaud LB, Gonzalez-Angulo AM, Hortobagyi GN, Esteva FJ. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: The MD Anderson Cancer Center experience. J Clin Oncol 24:4107-15, 2006. PMID: 16908934.
36. Baptista MZ, Prieto V, Chon S, Hortobagyi GN, Esteva FJ. Tamoxifen-induced vasculitis. J Clin Oncol 24(21):3504-3505, 2006. PMID: 16849770.
37. Esteva FJ, Cheli CD, Fritsche H, Fornier M, Slamon D, Thiel RP, Luftner D, Ghani F. Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies. Breast Cancer Res 7(4):436-43, 2005. PMCID: PMCPMC1175054.
38. Nahta R, Yuan LX, Zhang B, Kobayashi R, Esteva FJ. Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res 65(23):11118-28, 2005. PMID: 16322262.
39. Esteva FJ, Sahin AA, Cristofanilli M, Coombes K, Lee SJ, Baker J, Cronin M, Walker M, Watson D, Shak S, Hortobagyi GN. Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy. (Abstracted in Breast Diseases: A Year Book Quarterly 17(1):31-32, 2006). Clin Cancer Res 11(9):3315-9, 2005. PMID: 15867229.
40. Nahta R, Esteva FJ. In vitro effects of trastuzumab and vinorelbine in trastuzumab-resistant breast cancer cells. Cancer Chemother Pharmacol 53(2):186-90, 2004. PMID: 14605867.
41. Gonzalez-Angulo AM, Krishnamurthy S, Yamamura Y, Broglio KR, Pusztai L, Buzdar AU, Hortobagyi GN, Esteva FJ. Lack of association between amplification of her-2 and response to preoperative taxanes in patients with breast carcinoma. Cancer 101(2):258-63, 2004. PMID: 15241821.
42. Nahta R, Takahashi T, Ueno NT, Hung MC, Esteva FJ. P27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells. Cancer Res 64(11):3981-6, 2004. PMID: 15173011.
43. Esteva FJ, Sahin AA, Smith TL, Yang Y, Pusztai L, Nahta R, Buchholz TA, Buzdar AU, Hortobagyi GN, Bacus SS. Prognostic significance of phosphorylated P38 mitogen-activated protein kinase and HER-2 expression in lymph node-positive breast carcinoma. Cancer 100(3):499-506, 2004. PMID: 14745865.
44. Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA, Klos KS, Li P, Monia BP, Nguyen NT, Hortobagyi GN, Hung MC, Yu D. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6(2):117-27, 2004. PMID: 15324695.
45. Nahta R, Hung MC, Esteva FJ. The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res 64(7):2343-6, 2004. PMID: 15059883.
46. Esteva FJ, Rivera E, Cristofanilli M, Valero V, Royce M, Duggal A, Colucci P, DeJager R, Hortobagyi GN. A Phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with metastatic breast carcinoma. Cancer 98(5):900-7, 2003. PMID: 12942555.
47. Esteva FJ, Sahin AA, Rassidakis GZ, Yuan LX, Smith TL, Yang Y, Gilcrease MZ, Cristofanilli M, Nahta R, Pusztai L, Claret FX. Jun activation domain binding protein 1 expression is associated with low p27(Kip1)levels in node-negative breast cancer. Clin Cancer Res 9(15):5652-9, 2003. PMID: 14654548.
48. Esteva FJ, Glaspy J, Baidas S, Laufman L, Hutchins L, Dickler M, Tripathy D, Cohen R, DeMichele A, Yocum RC, Osborne CK, Hayes DF, Hortobagyi GN, Winer E, Demetri GD. Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer. J Clin Oncol 21(6):999-1006, 2003. PMID: 12637463.
49. Esteva FJ, Valero V, Booser D, Guerra LT, Murray JL, Pusztai L, Cristofanilli M, Arun B, Esmaeli B, Fritsche HA, Sneige N, Smith TL, Hortobagyi GN. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 20(7):1800-8, 2002. PMID: 11919237.

Invited Articles
1. Esteva FJ, Yu D, Hung MC, Hortobagyi GN. Molecular predictors of response to trastuzumab and lapatinib in breast cancer. Nat Rev Clin Oncol 7(2):98-107, 2010. PMID: 20027191.
2. Benson JR, Jatoi I, Keisch M, Esteva FJ, Makris A, Jordan VC. Early breast cancer. Lancet 373(9673):1463-79, 2009. PMID: 19394537.
3. Morrow PK, Zambrana F, Esteva FJ. Recent advances in systemic therapy: advances in systemic therapy for HER2-positive metastatic breast cancer. Breast Cancer Res 11(4):207, 2009. PMID: 19664181.
4. Jin Q, Esteva FJ. Cross-talk between the ErbB/HER family and the type I insulin-like growth factor receptor signaling pathway in breast cancer. J Mammary Gland Biol Neoplasia 13(4):485-98, 2008. PMID: 19034632.
5. Dean-Colomb W, Esteva FJ. Emerging agents in the treatment of anthracycline- and taxane-refractory metastatic breast cancer. Semin Oncol 35(2):31-38, 2008. PMID: 18410797.
6. Esteva FJ, Hortobagyi GN. Gaining ground on breast cancer. Sci Am 298(6):58-65, 2008. PMID: 18642543.
7. Dean-Colomb W, Esteva FJ. Her2-positive breast cancer: herceptin and beyond. Eur J Cancer 44(18):2806-12, 2008. PMID: 19022660.
8. Lenihan DJ, Esteva FJ. Multidisciplinary strategy for managing cardiovascular risks when treating patients with early breast cancer. Oncologist 13(12):1224-34, 2008. PMID: 19091778.
9. Nahta R, Esteva FJ. Trastuzumab: triumphs and tribulations. Oncogene 26(25):3637-3643, 2007. PMID: 17530017.
10. Esteva FJ, Hortobagyi GN. Comparative assessment of lipid effects of endocrine therapy for breast cancer: Implications for cardiovascular disease prevention. Breast 15(3):301-312, 2006.
11. Ocaña A, Hortobagyi GN, Esteva FJ. Concomitant versus sequential chemotherapy in the treatment of early-stage and metastatic breast cancer. Clin Breast Cancer 6(6):495-504, 2006.
12. Nahta R, Esteva FJ. HER2 therapy: Molecular mechanisms of trastuzumab resistance. Breast Cancer Res 6(8):215-220, 2006. PMID: 17096862.
13. Nahta R, Esteva FJ. Herceptin: mechanisms of action and resistance. Cancer Lett 232(2):123-38, 2006. PMID: 16458110.
14. Nahta R, Yu D, Hung MC, Hortobagyi GN, Esteva FJ. Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol 3(5):269-80, 2006. PMID: 16683005.
15. Meric-Bernstam F, Esteva FJ. Potential role of mammalian target of rapamycin inhibitors in breast cancer therapy. Clin Breast Cancer 6(4):357-60, 2005. PMID: 16277888.
16. Green MC, Esteva FJ Hortobagyi GN. Neoadjuvant chemotherapy. Breast Dis 21:23-31, 2004. PMID: 15687719.
17. Rajan R, Esteva FJ, Symmans WF. Pathologic changes in breast cancer following neoadjuvant chemotherapy: Implications for the assessment of response. Clin Breast Cancer 5(3):235-8, 2004. PMID: 15335458.
18. Nahta R, Hortobagyi GN, Esteva FJ. Growth factor receptors in breast cancer: Potential for therapeutic intervention. Oncologist 8(1):5-17, 2003. PMID: 12604728.
19. Nahta R, Esteva FJ. HER-2-targeted therapy: Lessons learned and future directions. Clin Cancer Res 9(14):5078-5084, 2003. PMID: 14613984.
20. Esteva FJ, Sahin AA, Cristofanilli M, Arun B, Hortobagyi GN. Molecular prognostic factors for breast cancer metastasis and survival. Semin Radiat Oncol 12(4):319-28, 2002. PMID: 12382190.
21. Esteva FJ, Valero V, Pusztai L, Boehnke-Michaud L, Buzdar AU, Hortobagyi GN. Chemotherapy of metastatic breast cancer: what to expect in 2001 and beyond. Oncologist 6(2):133-46, 2001. PMID: 11306725.
22. Esteva FJ, Hortobagyi GN. Integration of systemic chemotherapy in the management of primary breast cancer. Oncologist 3(5):300-313, 1998. PMID: 10388120.

Editorials
1. Esteva FJ. Does Analysis of Biomarkers in Tumor Cells in Lymph Node Metastases Give Additional Prognostic Information in Primary Breast Cancer? By Falck A.K., et al., World J Surg 2010. Breast Diseases: A Year Book Quarterly 22(1), 2011.
2. Esteva FJ, Hortobagyi GN. Topoisomerase IIa amplification and anthracycline-based chemotherapy: The Jury Is Still Out. J Clin Oncol 27(21):3416-3417, 2009. PMID: 19470912.
3. Esteva FJ. Can circulating HER-2 extracellular domain predict response to trastuzumab in HER-2-negative breast cancer? Oncologist 13(4):370-372, 2008. PMID: 18448550.
4. Esteva FJ, Hortobagyi GN. Can early response assessment guide neoadjuvant chemotherapy in early-stage breast cancer? J Natl Cancer Inst 100(9):521-3, 2008. PMID: 18398093.
5. Livingston RB, Esteva FJ. Chemotherapy and herceptin for HER-2+ metastatic breast cancer: the best drug? Oncologist 6:315-316, 2001.

Grant & Contract Support

Title: Functional, cellular, and molecular imaging and therapy monitoring using ultrasound
Funding Source: NIH/NCI
Role: Principal Investigator (multi-PI)
Duration: 9/25/2012 - 6/30/2017
 
Title: CD44 and HER2 therapy resistance
Funding Source: Breast Cancer Research Foundation
Role: Principal Investigator
Duration: 10/1/2011 - 9/30/2013
 
Title: The impact of obesity and obesity treatments on breast cancer
Funding Source: Susan G. Komen for the Cure
Role: Principal Investigator (multi-PI)
Principal Investigator: Yeung, Lee, Esteva
Duration: 7/1/2008 - 9/30/2013
 
Title: Translational Breast Cancer Research Consortium (https://web.emmes.com/study/bcrc/sites/clinical_sites.html)
Funding Source: Breast Cancer Research Foundation, Susan G Komen for the Cure, Avon Foundation
Role: Principal Investigator
Duration: 10/1/2005 - 9/30/2013
 
Title: Improving early detection of breast cancer with a blood test -- MD Anderson Specimen Core
Funding Source: Breast Cancer Biomarker Consortium
Role: Principal Investigator
Duration: 8/25/2005 - 8/31/2013

Last updated: 3/29/2013